Vikas Lifecare Limited (IN:VIKASLIFE)
:VIKASLIFE
Top Page
Vikas Lifecare Limited
(VIKASLIFE)
Select Model
Select Model
Rating:50Neutral
Price Target:
₹1.50
▼(-16.67% Downside)
Action:ReiteratedDate:04/08/26
The score is held down primarily by weak financial performance (loss-making operations, weakening margins, and poor cash generation) and a valuation profile that lacks support due to negative earnings and no dividend data. Technical indicators are largely neutral with a mild bearish tilt, providing limited offset.
Positive Factors
Balance sheet strength
Despite earnings weakness, a strong equity base and a moderate debt-to-equity position provide structural financial resilience. That capital buffer supports supplier credit, inventory financing and gives management time to repair margins or pursue operational fixes without immediate solvency risk.
Negative Factors
Negative profitability
Net losses and weakened gross/EBIT/EBITDA margins signal persistent operational issues. Negative profitability erodes retained earnings, limits reinvestment, and undermines returns metrics; without margin recovery the core trading model may struggle to sustain growth or absorb cost shocks.
Read all positive and negative factors
Positive Factors
Negative Factors
Balance sheet strength
Despite earnings weakness, a strong equity base and a moderate debt-to-equity position provide structural financial resilience. That capital buffer supports supplier credit, inventory financing and gives management time to repair margins or pursue operational fixes without immediate solvency risk.
Read all positive factors
Vikas Lifecare Limited (VIKASLIFE) vs. iShares MSCI India ETF (INDA)
Market Cap
₹2.97B
Dividend YieldN/A
Average Volume (3M)850.96K
Price to Earnings (P/E)―
Beta (1Y)0.76
Revenue Growth9.42%
EPS Growth-12220.00%
CountryIN
Employees36
SectorHealthcare
Sector Strength45
IndustryChemicals - Specialty
Share Statistics
EPS (TTM)N/A
Shares Outstanding1,857,668,600
10 Day Avg. Volume448,294
30 Day Avg. Volume850,962
Financial Highlights & Ratios
PEG Ratio0.26
Price to Book (P/B)0.87
Price to Sales (P/S)0.96
P/FCF Ratio-1.95
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Vikas Lifecare Limited Business Overview & Revenue Model
Company Description
Vikas Lifecare Limited engages in the trading of various chemicals compounds, polymers, PVC resins, plastic granules, and products related to plastic industry in India. It operates through Real Estate, Trading- Polymers, Trading-Cashew Nuts, and M...
How the Company Makes Money
Vikas Lifecare Limited primarily makes money by selling industrial materials—mainly polymers and chemical products—to business customers. Its core revenue model is trading/distribution: it sources products (from domestic and/or international manuf...
Vikas Lifecare Limited Financial Statement Overview
Summary
Income Statement
45
Neutral
Balance Sheet
60
Neutral
Cash Flow
50
Neutral
| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 4.80B | 4.80B | 4.46B | 4.76B | 3.01B | 749.95M |
| Gross Profit | 86.62M | 38.79M | 262.04M | 243.20M | 101.59M | 112.35M |
| EBITDA | -16.41M | 43.56M | 240.93M | -160.98M | 427.24M | 43.39M |
| Net Income | -112.78M | -106.14M | 140.29M | -152.99M | 286.99M | -35.02M |
Balance Sheet | ||||||
| Total Assets | 0.00 | 7.29B | 5.55B | 4.55B | 3.21B | 1.49B |
| Cash, Cash Equivalents and Short-Term Investments | 57.31M | 431.74M | 159.36M | 113.13M | 77.05M | 1.88M |
| Total Debt | 0.00 | 767.00M | 344.90M | 304.07M | 230.77M | 417.57M |
| Total Liabilities | -5.33B | 1.96B | 762.67M | 1.21B | 1.21B | 822.82M |
| Stockholders Equity | 5.33B | 5.32B | 4.77B | 3.31B | 1.99B | 666.70M |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | -2.36B | -577.20M | -1.28B | -281.03M | -91.52M |
| Operating Cash Flow | 0.00 | -2.24B | -417.48M | -1.10B | -148.84M | -76.82M |
| Investing Cash Flow | 0.00 | 1.03B | -906.01M | -366.38M | -385.14M | 119.21M |
| Financing Cash Flow | 0.00 | 1.12B | 1.37B | 1.51B | 590.87M | -42.69M |
Vikas Lifecare Limited Technical Analysis
Neutral
1.80
Price Trends
1.48
Positive
1.66
Negative
1.99
Negative
Market Momentum
-0.02
Negative
65.52
Neutral
87.60
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:VIKASLIFE, the sentiment is Neutral. The current price of 1.8 is above the 20-day moving average (MA) of 1.29, above the 50-day MA of 1.48, and below the 200-day MA of 1.99, indicating a neutral trend. The MACD of -0.02 indicates Negative momentum. The RSI at 65.52 is Neutral, neither overbought nor oversold. The STOCH value of 87.60 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IN:VIKASLIFE.
Vikas Lifecare Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
63 Neutral | ₹3.47B | 19.99 | ― | ― | -5.82% | -59.22% | |
55 Neutral | ₹3.26B | 56.53 | ― | 0.26% | -9.16% | 49.09% | |
54 Neutral | ₹2.09B | -338,564.26 | ― | ― | 4.04% | -35.02% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | ₹3.82B | 6.87 | ― | 0.66% | -13.51% | -122.00% | |
50 Neutral | ₹2.97B | -32.50 | ― | ― | 9.42% | -12220.00% | |
48 Neutral | ₹2.43B | 7.63 | ― | ― | -30.27% | -3470.06% |
* Healthcare Sector Average
IN:VIKASLIFE
Vikas Lifecare Limited
1.60
-1.19
-42.65%
IN:ALBERTDAVD
Albert David Ltd
669.25
-117.59
-14.94%
IN:LYKALABS
Lyka Labs Limited
58.69
-44.91
-43.35%
IN:MEDICAMEQ
Medicamen Biotech Limited
240.45
-254.31
-51.40%
IN:NECLIFE
Nectar Lifesciences Ltd.
10.82
-11.08
-50.59%
IN:ZIMLAB
Zim Laboratories Ltd.
71.30
-15.80
-18.14%
Vikas Lifecare Limited Corporate Events
Vikas Lifecare Extends Trading Window Closure Pending Delayed Results
Mar 30, 2026
Vikas Lifecare Limited has announced that its trading window for dealing in the company’s securities will remain closed in line with insider trading regulations, as its unaudited financial results for the quarter ended September 30, 2025 hav...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.